Stock listing
TSX:BCT BriaCell Therapeutics Corp Stock
Home listing (TSX) of BriaCell Therapeutics Corp
Follow BriaCell Therapeutics Corp into a list and get an email when it puts out news.
Share price · TSX:BCT
$4.40 CAD -0.25 (-5.5%)
Close on Nov 20, 2026
- Day range
- $4.34 – $4.45 CADNov 20, 2026
- Volume
- 1,305 sharesNov 20, 2026
- Market cap
- $38.42M CADAt the close on Nov 20, 2026 · price × 8.73M shares outstanding
- 52-week range
- $3.68 – $18.00 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $37,627 CADMedian day 4,349 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSX:BCT · Home | $4.40 CAD | -0.255 (-5.5%) | 1,305 | $4.45 | $4.45 | $4.34 | $4.655 | Close on Nov 20, 2026 |
| NASDAQ:BCTX | $3.06 USD | -0.10 (-3.2%) | 109,662 | $3.14 | $3.20 | $3.02 | $3.16 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSX:BCT · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.40 | -0.255 | -5.5% | $4.45 | $4.45 | $4.34 | 1,305 | |
| $4.655 | -0.295 | -6.0% | $5.00 | $5.00 | $4.655 | 5,575 | |
| $4.95 | +0.22 | +4.7% | $4.81 | $5.07 | $4.80 | 1,118 | |
| $4.73 | -0.16 | -3.3% | $4.74 | $4.74 | $4.73 | 600 | |
| $4.89 | -0.01 | -0.2% | $4.86 | $4.89 | $4.76 | 1,848 | |
| $4.90 | -0.18 | -3.5% | $5.17 | $5.17 | $4.90 | 1,120 | |
| $5.08 | -0.12 | -2.3% | $5.24 | $5.24 | $5.08 | 201 | |
| $5.20 | 0.00 | 0.0% | $5.30 | $5.32 | $5.18 | 1,223 | |
| $5.20 | -0.37 | -6.6% | $5.44 | $5.53 | $5.18 | 5,132 | |
| $5.57 | +0.96 | +20.8% | $4.60 | $5.79 | $4.60 | 21,391 | |
| $4.61 | +0.16 | +3.6% | $4.78 | $4.85 | $4.38 | 2,901 | |
| $4.45 | +0.25 | +6.0% | $4.28 | $4.62 | $4.28 | 4,282 | |
| $4.20 | -0.09 | -2.1% | $4.38 | $4.38 | $4.20 | 8,019 | |
| $4.29 | -0.01 | -0.2% | $4.35 | $4.52 | $4.29 | 6,326 | |
| $4.30 | -0.35 | -7.5% | $4.60 | $4.61 | $4.15 | 11,319 | |
| $4.65 | -0.21 | -4.3% | $5.02 | $5.02 | $4.64 | 7,126 | |
| $4.86 | -0.15 | -3.0% | $5.01 | $5.01 | $4.86 | 2,012 | |
| $5.01 | +0.14 | +2.9% | $4.99 | $5.10 | $4.77 | 4,150 | |
| $4.87 | +0.08 | +1.7% | $5.02 | $5.03 | $4.86 | 4,182 | |
| $4.79 | -0.05 | -1.0% | $4.78 | $4.79 | $4.72 | 1,187 | |
| $4.84 | -0.24 | -4.7% | $5.11 | $5.11 | $4.77 | 4,398 | |
| $5.08 | +0.22 | +4.5% | $4.86 | $5.08 | $4.86 | 1,504 | |
| $4.86 | +0.05 | +1.0% | $4.78 | $5.05 | $4.77 | 4,000 | |
| $4.81 | -0.07 | -1.4% | $4.86 | $4.87 | $4.81 | 1,926 | |
| $4.88 | -0.48 | -9.0% | $5.41 | $5.41 | $4.80 | 15,500 | |
| $5.36 | +0.11 | +2.1% | $5.26 | $5.36 | $5.26 | 900 | |
| $5.25 | -0.06 | -1.1% | $5.38 | $5.50 | $5.25 | 3,000 | |
| $5.31 | -0.30 | -5.3% | $5.56 | $5.56 | $5.30 | 4,300 | |
| $5.61 | +0.05 | +0.9% | $5.56 | $5.66 | $5.56 | 1,100 | |
| $5.56 | -0.13 | -2.3% | $5.57 | $5.62 | $5.55 | 4,000 | |
| $5.69 | -0.01 | -0.2% | $5.70 | $5.73 | $5.63 | 1,700 | |
| $5.70 | -0.23 | -3.9% | $5.92 | $5.92 | $5.67 | 3,600 | |
| $5.93 | +0.18 | +3.1% | $5.80 | $6.01 | $5.76 | 3,700 | |
| $5.75 | -0.13 | -2.2% | $6.02 | $6.11 | $5.71 | 4,700 | |
| $5.88 | -0.22 | -3.6% | $6.09 | $6.09 | $5.87 | 4,800 | |
| $6.10 | +0.30 | +5.2% | $5.69 | $6.15 | $5.69 | 11,800 | |
| $5.80 | +0.07 | +1.2% | $5.68 | $5.80 | $5.67 | 5,100 | |
| $5.73 | -0.31 | -5.1% | $5.93 | $6.23 | $5.70 | 12,700 | |
| $6.04 | +0.02 | +0.3% | $6.14 | $6.16 | $5.96 | 10,200 | |
| $6.02 | +0.36 | +6.4% | $5.65 | $6.20 | $5.65 | 12,000 | |
| $5.66 | -0.08 | -1.4% | $5.69 | $5.82 | $5.66 | 3,000 | |
| $5.74 | -0.06 | -1.0% | $5.82 | $6.11 | $5.56 | 10,000 | |
| $5.80 | -0.11 | -1.9% | $5.73 | $5.925 | $5.64 | 5,500 | |
| $5.91 | -0.01 | -0.2% | $5.86 | $6.11 | $5.73 | 15,600 | |
| $5.92 | +0.94 | +18.9% | $4.92 | $6.03 | $4.92 | 53,200 | |
| $4.98 | +0.06 | +1.2% | $4.95 | $5.02 | $4.90 | 2,300 | |
| $4.92 | -0.06 | -1.2% | $4.88 | $4.94 | $4.85 | 6,200 | |
| $4.98 | -0.06 | -1.2% | $5.04 | $5.06 | $4.96 | 13,200 | |
| $5.04 | +0.05 | +1.0% | $5.06 | $5.17 | $5.03 | 3,000 | |
| $4.99 | -0.06 | -1.2% | $4.95 | $5.03 | $4.94 | 2,000 | |
| $5.05 | +0.20 | +4.1% | $4.99 | $5.13 | $4.90 | 15,500 | |
| $4.85 | -0.08 | -1.6% | $4.72 | $4.95 | $4.72 | 2,300 | |
| $4.93 | +0.06 | +1.2% | $4.84 | $4.93 | $4.81 | 3,100 | |
| $4.87 | -0.08 | -1.6% | $4.82 | $4.87 | $4.82 | 200 | |
| $4.95 | -0.10 | -2.0% | $5.01 | $5.05 | $4.93 | 6,800 | |
| $5.05 | +0.08 | +1.6% | $4.94 | $5.06 | $4.91 | 5,600 | |
| $4.97 | -0.22 | -4.2% | $5.17 | $5.25 | $4.83 | 13,600 | |
| $5.19 | +0.03 | +0.6% | $5.08 | $5.20 | $5.07 | 1,100 | |
| $5.16 | -0.46 | -8.2% | $5.45 | $5.45 | $5.06 | 18,400 | |
| $5.62 | +0.48 | +9.3% | $5.14 | $5.62 | $5.14 | 9,900 | |
| $5.14 | +0.32 | +6.6% | $4.94 | $5.57 | $4.94 | 18,600 | |
| $4.82 | -0.74 | -13.3% | $5.55 | $5.55 | $4.78 | 25,400 | |
| $5.56 | +0.08 | +1.5% | $5.61 | $5.73 | $5.50 | 9,300 | |
| $5.48 | +0.03 | +0.6% | $5.43 | $5.75 | $5.43 | 7,400 |
Splits
3 splits since 2014 · TSX:BCT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-3.2573 | Consolidation |
- Ticker
- TSX:BCT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TSX
- Currency
- CAD
What changed lately
Latest news release · Nov 6, 2026
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
Latest deck · Nov 18, 2026
Investor Presentation (November 2026)
Investor deck · 27 slides
Latest news
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
Nov 6, 2026
Closed $5.57 (+20.8%) on Nov 6, 2026
BriaCell Awarded 2026 "Immunotherapy Solution of the Year" By BioTech Breakthrough
Nov 5, 2026
Closed $4.61 (+3.6%) on Nov 5, 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
Nov 3, 2026
Closed $4.20 (-2.1%) on Nov 3, 2026
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
Oct 23, 2026
Closed $4.79 (-1.0%) on Oct 23, 2026
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
Oct 6, 2026
Closed $5.70 (-3.9%) on Oct 6, 2026
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
Sep 14, 2026
Closed $4.98 (-1.2%) on Sep 14, 2026
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
Sep 8, 2026
Closed $4.85 (-1.6%) on Sep 8, 2026
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+(TM)
Aug 24, 2026
Closed $4.82 (-13.3%) on Aug 24, 2026
BriaCell Receives FDA Clearance to Initiate Bria-PROS+(TM) Clinical Study in Prostate Cancer
Aug 5, 2026
Closed $4.93 (+4.7%) on Aug 5, 2026
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
Jul 16, 2026
Closed $5.34 (-3.3%) on Jul 16, 2026
BriaCell Therapeutics Corp on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 45 in the last 12 months · 136 in all · newest Nov 6, 2026 · oldest 2007
- Decks
- 13 decks · latest Nov 18, 2026
Where BriaCell Therapeutics Corp is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSX:BCT · Home listing · This page | TSX | Canada | CAD |
| NASDAQ:BCTX | NASDAQ | United States | USD |
| Cboe Canada:BCT | Cboe Canada | Canada | CAD |
| BOATS:BCTX | BOATS | United States | USD |
| gettex:8BT | gettex | Germany | EUR |
| Tradegate:8BT | Tradegate | Germany | EUR |
| Frankfurt:8BT | Frankfurt | Germany | EUR |
| Munich:8BT | Munich | Germany | EUR |
Valuation
Price/book 1.7× against a median of 2.3×: 5th lowest of 11 Biotechnology companies shown. Statements: Year to Jul 31, 2026 · price Nov 20, 2026
- Enterprise value
- $8.97M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P/TSX Composite
- 1.07
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BriaCell Therapeutics Corp · TSX:BCT | US$26.79M | US$6.25M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.07 |
| Holy Stone Healthcare Co., Ltd. · TPEX:4194 | US$27.49M | US$25.08M | n/a | n/a | n/a | 7.3× | n/a | 0.0× | n/a |
| SoftOx Solutions AS · OSL:SOFTX | US$27.28M | US$25.25M | n/a | n/a | n/a | 11.6× | n/a | 0.0× | n/a |
| Edesa Biotech, Inc. · NASDAQ:EDSA | US$27.02M | US$16.72M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | 0.47 |
| Amplia Therapeutics Ltd. · ASX:ATX | US$26.84M | US$8.63M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Nasus Pharma Ltd. · AMEX:NSRX | US$26.82M | US$15.11M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 0.99 |
| Telomir Pharmaceuticals, Inc. · NASDAQ:TELO | US$26.82M | US$22.30M | n/a | n/a | n/a | 6.1× | n/a | 0.0× | 1.74 |
| Aprogen, Inc · KRX:007460 | US$26.80M | US$21.45M | n/a | 0.2× | n/a | 0.6× | −60.1% | 0.6× | n/a |
| Alterity Therapeutics Ltd. · ASX:ATH | US$26.76M | US$2.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| EyePoint, Inc. · NASDAQ:EYPT | US$26.65M | −US$72.44M | n/a | −28.1× | n/a | 0.3× | n/a | 0.2× | 1.36 |
| PolTREG Spolka Akcyjna · GPW:PTG | US$26.08M | US$22.35M | n/a | 378× | n/a | 2.2× | n/a | 0.1× | n/a |
| Median of the others | US$26.82M | US$19.08M | 0.2× | 2.3× | −60.1% | 0.0× | 1.18 |
Forecasts
Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 20.00 CAD · Analysts' mean
- EPS, year to Jul 2026
- -11.45 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| William V. Williams | President & Chief Executive Officer |
| Gadi Levin | Chief Financial Officer & Corporate Secretary |
| Giuseppe Del Priore | Chief Medical Officer |
| Jane A. Gross | Director of the Board |
| Martin E. Schmieg | Director of the Board |
| Massimo Cristofanilli | Chief, Breast Medical Oncology; Associate Director, Precision Medicine Oncology; Scientific Director, Englander Institute of Precision Medicine |
| Miguel A. Lopez-Lago | Chief Scientific Officer |
| Rebecca Taub | Director of the Board |
| Vaughn C. Embro-Pantalony | Director of the Board |
Board
| Director | Role |
|---|---|
| Jamieson Bondarenko | Chairman of the Board |
| Adam M. Brufsky | Co-Director, Comprehensive Breast Cancer Center; Medical Director, Women’s Cancer Center |
| Massimo Cristofanilli | Chief, Breast Medical Oncology; Associate Director, Precision Medicine Oncology; Scientific Director, Englander Institute of Precision Medicine |
| William V. Williams | President & Chief Executive Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Oct 15, 2025 · After close | +4.2% |
| Q3 2025 | Jun 16, 2025 · After close | −0.5% |
| Q2 2025 | Mar 12, 2025 · After close | −1.4% |
| Q1 2025 | Dec 16, 2024 · After close | +2.3% |
| Q4 2024 | Oct 23, 2024 · After close | −2.4% |
| Q3 2024 | Jun 14, 2024 · After close | +4.2% |
| Q2 2024 | Mar 18, 2024 · After close | −6.7% |
| Q1 2024 | Dec 14, 2023 · After close | −1.6% |
| Q4 2023 | Oct 25, 2023 · After close | −10.7% |
| Q3 2023 | Jun 14, 2023 · After close | +3.3% |
All 15 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Mar 15, 2023 · After close | +1.0% |
| Q1 2023 | Dec 14, 2022 · After close | −2.4% |
| Q4 2022 | Oct 27, 2022 · After close | +2.3% |
| Q3 2022 | Jun 13, 2022 · After close | −0.8% |
| Q2 2022 | Mar 14, 2022 · After close | −0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 27 slides | Nov 18, 2026 |
| Investor Presentation (September 2026) | Investor deck | 27 slides | Sep 28, 2026 |
| Technical Presentation (June 2024) | Technical | 21 slides | Jun 3, 2024 |
| Investor Presentation (April 2021) | Investor deck | 17 slides | April 2021 |
| Investor Presentation (February 2021) | Investor deck | 15 slides | February 2021 |
| 3rd Annual Biologics World Nordic 2020 Conference | Conference | 31 slides | Sep 30, 2020 |
| Investor Presentation (July 2019) | Investor deck | 41 slides | July 2019 |
| Investor Presentation (October 2018) | Investor deck | 42 slides | October 2018 |
| Investor Presentation (October 2018) | Investor deck | 43 slides | October 2018 |
| Investor Presentation (September 2018) | Investor deck | 38 slides | September 2018 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2018) | Investor deck | 39 slides | July 2018 |
| Investor Presentation (May 2018) | Investor deck | 37 slides | May 2018 |
| Investor Presentation (July 2016) | Investor deck | 24 slides | July 2016 |
Financings
| Raise | Date |
|---|---|
| Public offering of units (one common share or pre-funded warrant and one warrant) Closed: US$30M raised · US$5.59 a unit · 1 warrant at US$6.93 for 60 months · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: Working capital, general corporate purposes and advancing the company's business objectives | Jan 15, 2026 |
| Public offering of units (one common share or pre-funded warrant and one warrant) Closed: US$15M raised · US$1.25 a unit · 1 warrant at US$1.5 for 60 months · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: Working capital, general corporate purposes and advancing business objectives | Jul 16, 2025 |
| Public offering of units (one common share or pre-funded warrant and one warrant) Closed: US$13.8M raised · US$4.5 a unit · 1 warrant at US$5.25 for 60 months · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: Working capital, general corporate purposes and advancement of business objectives | Apr 28, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Drill core
| Release | Date | Project | Headline hole |
|---|---|---|---|
| Ansell Capital Corp announces additional drill results at Charlotte Property, Yukon DDH-11-255 1.03 g/t Au over 2.90 m from 108.10 m DDH-11-256 0.41 g/t Au over 4.60 m from 23.30 m | Nov 8, 2011 | Charlotte property | DDH-11-254 3.38 g/t Au over 12.40 m from 92.40 m |
| ANSELL CAPITAL CORP. SUMMARIZES DRILL RESULTS FROM THE CHARLOTTE PROPERTY NEAR CARMACKS, YUKON TERRITORY DDH-10-241 1.77 g/t Au over 24.25 m from 58.25 m DDH-10-242 8.61 g/t Au over 5.65 m from 15.85 m | Nov 8, 2010 | Charlotte property | DDH-10-240 1.66 g/t Au over 31.25 m from 59.60 m |
Properties
| Property | Place | On 6ix | Last news |
|---|---|---|---|
| Charlotte property | Yukon, Canada | 2 drill releases | Nov 8, 2011 |
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 | FY2021 | FY2021 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 29.2M | 21.3M | 27.2M | 15.3M | 8.02M | 2.02M | ||
| Operating income | -36.1M | -27.2M | -33.3M | -23.3M | -15.3M | -6.98M | ||
| Depreciation and amortization | 104.1K | 91.4K | 68.6K | 15.3K | 15.3K | |||
| EBITDA | -36.0M | -27.1M | -33.3M | -15.3M | -6.96M | |||
| Interest expense | 29.6K | 37.0K | 979 | 78.6K | ||||
| Income before tax | 35.3M | 26.6M | 4.93M | 20.3M | -26.8M | -13.8M | ||
| Income tax | 0 | 0 | ||||||
| Net income | -34.9M | -26.3M | -4.79M | -20.3M | -26.8M | -13.8M | ||
| Earnings per share, basic | -6.97 | -62.19 | -43.68 | -1.30 | -1.73 | -3.06 | ||
| Earnings per share, diluted | -6.97 | -62.19 | -43.68 | -1.30 | -1.73 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 | FY2021 | FY2021 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 9.85M | 10.5M | 862.1K | 21.3M | 41.0M | 57.3M | ||
| Short-term investments | 10.7M | 7.37M | ||||||
| Receivables | 18.9K | 24.1K | 12.6K | |||||
| Current assets | 22.0M | 19.9M | 3.65M | 26.9M | 42.3M | 57.8M | ||
| Property, plant and equipment | 319.8K | 296.8K | 388.2K | 2.50K | 2.50K | |||
| Total assets | 23.6M | 21.6M | 5.87M | 27.2M | 42.6M | 58.0M | ||
| Current liabilities | 7.98M | 3.98M | 7.46M | 1.80M | 941.1K | 556.8K | ||
| Shareholders' equity | 15.6M | 17.3M | -2.68M | -3.78M | 10.3M | 27.7M | ||
| Shares outstanding | 8.71M | 1.88M | 121.9K | 16.0M | 15.5M | 15.5M | 15.3M | 15.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Cash from operations | -28.7M | -28.2M | -24.1M | -23.7M | -12.5M | -7.75M |
| Capital spending | -127.0K | -456.8K | ||||
| Free cash flow | -28.8M | -24.6M | ||||
| Cash from investing | -3.81M | -7.65M | -681.8K | |||
| Cash from financing | 31.8M | 45.4M | 4.42M | 3.95M | -3.74M | 65.0M |
| Change in cash | -641.4K | 9.63M | -20.4M | -19.8M | -16.2M | 57.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-K · Annual report | Oct 28, 2026 | Annual report | SEC |
| 8-K · Current report | Jun 26, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Jun 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jun 2, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 2, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 31, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Mar 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Mar 9, 2026 | Meeting outcome | SEC |
| 25-NSE | Feb 26, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 20, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| DEF 14A · Proxy statement | Feb 12, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 23, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 15, 2026 | Material contract | SEC |
| 424B4 · Prospectus | Jan 14, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 14, 2026 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Jan 13, 2026 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Jan 13, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Jan 13, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 8, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 8, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 6, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 6, 2026 | Other filings | SEC |
| 8-K · Current report | Dec 29, 2025 | Current report | SEC |
| FWP · Free writing prospectus | Dec 23, 2025 | Offer document | SEC |
| S-1 · Registration statement | Dec 23, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Dec 11, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 28, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 7, 2025 | Big-stake notice | SEC |
| DRSLTR · Letter to the SEC with a draft | Oct 16, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Oct 16, 2025 | Offer document | SEC |
| 10-K · Annual report | Oct 15, 2025 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 25, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Jul 31, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 28, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 22, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 21, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 16, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jul 16, 2025 | Other filings | SEC |
| 424B4 · Prospectus | Jul 15, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 14, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 14, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 11, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 11, 2025 | Other filings | SEC |
| FWP · Free writing prospectus | Jul 10, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jul 10, 2025 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jul 9, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Jul 8, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 8, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 8, 2025 | Other filings | SEC |
| S-1 · Registration statement | Jul 8, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 24, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jun 18, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Jun 18, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 18, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Jun 16, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 28, 2025 | Material contract | SEC |
| 424B4 · Prospectus | Apr 28, 2025 | Offer document | SEC |
| 424B4 · Prospectus | Apr 28, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 25, 2025 | Other filings | SEC |
| S-1MEF · Registration of more shares for the same offering | Apr 24, 2025 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Apr 24, 2025 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Apr 24, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 23, 2025 | Offer document | SEC |
| FWP · Free writing prospectus | Apr 22, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2025 | Other filings | SEC |
| S-1 · Registration statement | Apr 22, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 24, 2025 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Mar 12, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Mar 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Mar 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Mar 12, 2025 | Current report | SEC |
| 8-K · Current report | Feb 13, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 6, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Feb 5, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Feb 4, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Feb 3, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 28, 2025 | Current report | SEC |
| 8-K · Current report | Jan 3, 2025 | Current report | SEC |
| 8-K · Current report | Jan 3, 2025 | Current report | SEC |
| DEFA14A · Additional proxy material | Jan 3, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 17, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Dec 16, 2024 | Quarterly report | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| 8-K · Current report | Dec 13, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Dec 12, 2024 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 12, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Dec 11, 2024 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 10, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 5, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 25, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 1, 2024 | Current report | SEC |
| 10-K · Annual report | Oct 28, 2024 | Annual report | SEC |
| 8-K · Current report | Oct 2, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Oct 2, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 1, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Sep 16, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 12, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Sep 11, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 11, 2024 | Current report | SEC |
| 8-K · Current report | Aug 23, 2024 | Current report | SEC |
| 8-K · Current report | Jul 18, 2024 | Current report | SEC |
| 8-K · Current report | Jul 5, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Jun 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jun 14, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | May 24, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 8-K · Current report | May 17, 2024 | Material contract | SEC |
| 424B5 · Prospectus | May 16, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Mar 18, 2024 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Feb 1, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 31, 2024 | Meeting outcome | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 29, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jan 22, 2024 | Offer document | SEC |
| DEF 14A · Proxy statement | Jan 9, 2024 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Dec 20, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Dec 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Dec 14, 2023 | Current report | SEC |
| 8-K · Current report | Nov 30, 2023 | Current report | SEC |
| 8-K · Current report | Nov 3, 2023 | Current report | SEC |
| 10-K · Annual report | Oct 25, 2023 | Annual report | SEC |
| 8-K · Current report | Oct 25, 2023 | Current report | SEC |
| 8-K · Current report | Sep 8, 2023 | Current report | SEC |
| 8-K · Current report | Sep 7, 2023 | Current report | SEC |
| 8-K · Current report | Aug 31, 2023 | Current report | SEC |
| 8-K · Current report | Aug 31, 2023 | Current report | SEC |
| 8-K · Current report | Aug 25, 2023 | Current report | SEC |
| 8-K · Current report | Aug 21, 2023 | Meeting outcome | SEC |
| DEF 14A · Proxy statement | Jul 26, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jun 30, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jun 27, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Jun 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 31, 2023 | Material contract | SEC |
| 8-K · Current report | May 22, 2023 | Financing | SEC |
| 8-K · Current report | May 15, 2023 | Material contract | SEC |
| 8-K · Current report | Apr 17, 2023 | Current report | SEC |
| 8-K · Current report | Mar 30, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 29, 2023 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Mar 20, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 16, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Mar 15, 2023 | Quarterly report | SEC |
| CORRESP · Letter to the SEC | Mar 13, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 8, 2023 | Other filings | SEC |
| 8-K · Current report | Feb 23, 2023 | Current report | SEC |
| 8-K · Current report | Feb 15, 2023 | Meeting outcome | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Feb 10, 2023 | Current report | SEC |
| 8-K · Current report | Jan 24, 2023 | Current report | SEC |
| 8-K · Current report | Jan 23, 2023 | Current report | SEC |
| 8-K · Current report | Jan 18, 2023 | Current report | SEC |
| DEF 14A · Proxy statement | Jan 17, 2023 | Meeting notice | SEC |
| 8-K · Current report | Jan 10, 2023 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jan 5, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 28, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Dec 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Dec 8, 2022 | Current report | SEC |
| 8-K · Current report | Nov 30, 2022 | Current report | SEC |
| 8-K · Current report | Nov 10, 2022 | Current report | SEC |
| 10-K · Annual report | Oct 27, 2022 | Annual report | SEC |
| 8-K · Current report | Oct 27, 2022 | Results | SEC |
| 8-K · Current report | Oct 21, 2022 | Current report | SEC |
| 8-K · Current report | Sep 14, 2022 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 11, 2022 | Insider trade | SEC |
| 8-K · Current report | Aug 4, 2022 | Material contract | SEC |
| 3 · Initial statement of ownership | Aug 2, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 1, 2022 | Insider trade | SEC |
| SC 13G · Big-stake notice | Aug 1, 2022 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Jul 18, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 5, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 29, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 24, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 13, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 18, 2022 | Current report | SEC |
| SC 13G · Big-stake notice | Apr 25, 2022 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Apr 13, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 12, 2022 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 7, 2022 | Current report | SEC |
| 424B3 · Prospectus | Mar 21, 2022 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 17, 2022 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Mar 15, 2022 | Current report | SEC |
This page holds 200 of 324 filings. Open Filings
Cap table
Built by 6ix from BriaCell Therapeutics Corp’s releases · as of Jan 15, 2026
- Common shares
- 8,732,381
- Fully diluted
- 29,565,772
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 8,732,381 | |
| Warrants | 20,833,391 | Jan 15, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$6.93 · expire about Jan 2031 |
| Warrants · US$1.50 · expire about Jul 2030 |
| Warrants · US$5.25 · expire about Apr 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 8,732,381 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gadi Levin Other companies: Clearmind Medicine Inc. (VP Finance · Since at least Nov 4, 2026); Sativus Tech Corp. (CEO · Dec 15, 2021 – Dec 15, 2021 · Past); Quantum X Labs Inc. (Chief Financial Officer · Apr 18, 2017 – Apr 18, 2017 · Past) | Chief Financial Officer & Corporate Secretary · Since at least Aug 1, 2022 |
| Adam M. Brufsky | Co-Director, Comprehensive Breast Cancer Center; Medical Director, Women’s Cancer Center · Since at least Jun 1, 2026 |
| Giuseppe Del Priore | Chief Medical Officer · Since at least Oct 23, 2026 |
| Jamieson Bondarenko | Chairman of the Board · Since at least Mar 31, 2026 |
| Jane A. Gross | Director of the Board · Since at least Mar 5, 2026 |
| Martin E. Schmieg | Director of the Board · Since at least Mar 5, 2026 |
| Massimo Cristofanilli | Chief, Breast Medical Oncology; Associate Director, Precision Medicine Oncology; Scientific Director, Englander Institute of Precision Medicine · Since at least Nov 4, 2026 |
| Miguel A. Lopez-Lago | Chief Scientific Officer · Since at least Nov 3, 2026 |
| Rebecca Taub | Director of the Board · Since at least Mar 5, 2026 |
| Vaughn C. Embro-Pantalony | Director of the Board · Since at least Mar 5, 2026 |
All 11 people
| Person | Seat |
|---|---|
| William V. Williams | President & Chief Executive Officer · Since at least Nov 3, 2026 |
Log in to ask 6ix AI your own questions about BriaCell Therapeutics Corp.